Pfizer (PFE) Shares are Down -0.47%

Pfizer (PFE) : During the past 4 weeks, traders have been relatively bearish on Pfizer (PFE), hence the stock is down -0.97% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1% relative to the S&P 500. The 4-week change in the price of the stock is -2.97% and the stock has fallen -0.47% in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.18% and the 50-Day Moving Average is 4.11%.The 200 Day SMA reached 4.46% Pfizer Inc. is up 0.01% in the last 3-month period. Year-to-Date the stock performance stands at 8.04%.


Pfizer (PFE) : The consensus price target for Pfizer (PFE) is $39.5 for the short term with a standard deviation of $5.62. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $54, however, the pessimist price target for the company is $33.

For the current week, the company shares have a recommendation consensus of Buy. Pfizer (NYSE:PFE): stock was range-bound between the intraday low of $33.83 and the intraday high of $34.22 after having opened at $34.19 on Fridays session. The stock finally closed in the red at $34.19, a loss of -0.59%. The stock remained in the red for the whole trading day. The total traded volume was 25,615,509 shares. The stock failed to cross $34.22 in Fridays trading. The stocks closing price on Thursday was $34.14.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *